Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Bristol-Myers Squibb's Second-Quarter Reflects a Company in Transition

Bristol-Myers Squibb (NYSE: BMY  )  released its second-quarter earnings before the bell today, posting a non-GAAP EPS of $0.48 on $3.889 billion in revenue. The Street was expecting slightly lower numbers for EPS at $0.44 and revenue at $3.85 billion for the quarter. 

Despite beating the Street's estimates, revenue still fell by 4% in the second quarter compared to the same period a year ago. This drop was due mostly to its exit from the diabetes market after selling the bulk of these assets to AstraZeneca earlier this year. When this revenue loss is excluded, Bristol's second-quarter revenues actually increased by 7% for the year.

Bristol saw most of its top-line growth for the quarter generated by a handful of products, namely Yervoy, Sprycel, Orencia, and Eliquis. In particular, Yervoy posted an impressive 38% increase in sales to $321 million for the quarter, compared to a year ago. Sprycel sales also rose nicely in the quarter by 18% to $368 million.

Looking ahead, Bristol is pushing hard to gain two regulatory approvals for its PD-1 inhibitor nivolumab (Trade name Opdivo) within the next 12 months. If it can gain approvals as a treatment for advanced melanoma and non-small cell lung cancer next year, Bristol's outlook should change in a hurry. Until then, the Street is expecting the company to post increasingly weak quarterly numbers due to its ongoing restructuring process.  

Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. Click here now.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 3042570, ~/Articles/ArticleHandler.aspx, 9/3/2015 9:58:23 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

George Budwell

George Budwell has been writing about healthcare and biotechnology companies at the Motley Fool since 2013. His primary interests are novel small molecule drugs, next generation vaccines, and cell therapies.

Today's Market

updated 42 minutes ago Sponsored by:
DOW 16,374.76 23.38 0.14%
S&P 500 1,951.13 2.27 0.12%
NASD 4,733.50 -16.48 -0.35%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/3/2015 4:01 PM
BMY $58.75 Down -0.86 -1.44%
Bristol-Myers Squi… CAPS Rating: ****